Replies to post #236908 on NorthWest Biotherapeutics Inc (NWBO)

[PHYInvestor]

Agreed.

And LP, and the management board should be sued for their damage to shareholders.

They run a public company like a private one.

She made millions from our investment

[CaptainObvious]

Yeah, if we start seeing a lot of hype for Direct, in my opinion L is being put on the far back burner, and it's time to check out. This board will be ghosted by many until fresh saps come in on the Direct trials. If NWBO survives

[sentiment_stocks]

The odds of L failing are very low, IMO. Will the trial be stat sig? That remains to be seen. But there will be multiple pathways forward to prevent any potential failing to get this treatment into the hands of patients, should the trial not be stat sig. And this will only be know after they unblind the data. The company can only make educated guesses at this time as to what the data might ultimately demonstrate.

If DCVax-L fails odds are better than even Direct is the proverbial bill of goods too

[meirluc]

If DCVax-L fails odds are better than even Direct is the proverbial bill of goods too and even if it is somehow not, for the good of cancer patients and future investors (it is too late for us) the creative destruction of the free marketplace needs to finally take place, NWBO needs to go away completely and the intellectual property needs to be put in the hand of more transparent and effective executives who work for shareholders with a lot more wisdom and backbone than we collectively have.

You are posting sweeping statements and conclusions that are far too premature. Why don't you wait until top line results are out and some more data obtained from additional Direct trials are on the table?

[erik007tc]

Dcvax-L will not fail... it will be approved and then immediate buyout with direct for $25+ boom! Patients win, shareholders prosper, and shorts killed.

[Rootjim]

The problem I see with DCVax-L is no one is 100% sure that it will be FDA approved.I have not heard of anyone saying it is a slam dunk for FDA approval. Buy all we can and get 100 times on our money??
We are still measuring risk to reward.All the management can do at NWBO, is to try increasing the odds of DCVax-L success, at this point and time.
At the price NWBO is now, I would like to invest more. It would be hard to imagine the trial going beyond the last patient enrolled for 5 years. If DCVax-L is approved it would be a huge hurdle for the competition to overcome. IMO